Get started
Author

Yoji Morisaki

Observed names: Morisaki, Yoji, Y. Morisaki, Yoji MORISAKI
OpenAlex ID: A5111197473
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study ( UNCOVER ‐J)
2016 · Hidehisa Saeki, Hidemi Nakagawa, et al. · The Journal of Dermatology · 195
PDF
Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis
2014 · H. Saeki, H. Nakagawa, et al. · Journal of the European Academy of Dermatology and Venereology · 132
Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo‐ and tamsulosin‐controlled 12‐week study in A sian men
2012 · Osamu Yokoyama, Masaki Yoshida, et al. · International Journal of Urology · 86
Long‐term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open‐label, phase 3 study ( UNCOVER ‐J)
2018 · Y. Okubo, T. Mabuchi, et al. · Journal of the European Academy of Dermatology and Venereology · 65
PDF
Tadalafil 5 mg once‐daily therapy for men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a randomized, double‐blind, placebo‐controlled trial carried out in J apan and K orea
2014 · Masayuki Takeda, Osamu Yokoyama, et al. · International Journal of Urology · 46
Tadalafil for the Treatment of Lower Urinary Tract Symptoms in Japanese Men with Benign Prostatic Hyperplasia: Results from a 12‐week Placebo‐controlled Dose‐finding Study with a 42‐week Open‐label Extension
2012 · Masayuki TAKEDA, Osamu NISHIZAWA, et al. · LUTS Lower Urinary Tract Symptoms · 39
Long‐term efficacy and safety results from an open‐label phase III study ( UNCOVER ‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab
2018 · Y. Umezawa, H. Torisu‐Itakura, et al. · Journal of the European Academy of Dermatology and Venereology · 35
Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis
2021 · Akimichi Morita, Yukari Okubo, et al. · Dermatology and Therapy · 34
PDF
Efficacy, Safety, Tolerability, and Pharmacokinetic Profile of Evacetrapib Administered as Monotherapy or in Combination With Atorvastatin in Japanese Patients With Dyslipidemia
2014 · Tamio Teramoto, Masakazu Takeuchi, et al. · The American Journal of Cardiology · 29
PDF
Evaluation of Quality of Life in Children with GH Deficiency and Idiopathic Short Stature Using the Child Behavior Checklist
2009 · Toshiaki Tanaka, Shigeru Tai, et al. · Clinical Pediatric Endocrinology · 26
PDF
Tadalafil 5 mg once daily for the treatment of Asian men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: Analyses of data pooled from three randomized, double‐blind, placebo‐controlled studies
2015 · Osamu Nishizawa, Masaki Yoshida, et al. · International Journal of Urology · 25
PDF
The Efficacy and Safety of Tadalafil 5 mg Once Daily in Korean Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: An Integrated Analysis
2014 · Sung Won Lee, Jae Seung Paick, et al. · The World Journal of Men s Health · 20
PDF
Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-severe Atopic Dermatitis
2024 · Akio Tanaka, Ken Igawa, et al. · Acta Dermato Venereologica · 15
PDF
Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
2024 · Norito Katoh, Akio Tanaka, et al. · Current Medical Research and Opinion · 11
Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J)
2024 · Norito Katoh, Akio Tanaka, et al. · British Journal of Dermatology · 9
Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
2023 · Hideto Kameda, Kohei Hagimori, et al. · Rheumatology and Therapy · 8
PDF
Japanese growth prediction model for prepubertal children with growth hormone deficiency
2012 · Yoshiki Seino, Sumie Yamashita, et al. · Journal of Pediatric Endocrinology and Metabolism · 6
51075 HADS anxiety and depression scores improved in Japanese patients with moderate-to-severe atopic dermatitis following lebrikizumab treatment: 16-week results from a randomized, double-blind, placebo-controlled phase 3 trial (ADhere-J)
2024 · Takeshi Nakahara, Yuichiro Tsunemi, et al. · Journal of the American Academy of Dermatology
48964 Lebrikizumab Combined with Topical Corticosteroids Improves Patient-reported Outcomes in Japanese Patients with Moderate-to-Severe Atopic Dermatitis
2024 · Akio Tanaka, Ken Igawa, et al. · Journal of the American Academy of Dermatology
Correction: Ixekizumab Efficacy in Patients with Severe Peripheral Psoriatic Arthritis: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (SPIRIT-P1)
2024 · Hideto Kameda, Kohei Hagimori, et al. · Rheumatology and Therapy
Works count: 22
Citation count: 781
H-index: 13
I10-index: 14
Year
Topic
Type